Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.7K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia.

Blood neoplasia·2026
Same author

An inflammatory and quiescent HSC subpopulation expands with age in humans.

Genome biology·2026
Same author

The PERKs of ER homeostasis for hematopoietic stem cells.

Blood·2025
Same author

NK cell heparanase controls tumor invasion and immune surveillance.

The Journal of clinical investigation·2024
Same author

The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapy.

Immunology and cell biology·2024
Same author

Author Correction: Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cell.

Nature immunology·2024

Related Experiment Video

Updated: Dec 12, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.2K

Targeting immune checkpoints in hematological malignancies.

Basit Salik1, Mark J Smyth1, Kyohei Nakamura2

  • 1Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland, 4006, Australia.

Journal of Hematology & Oncology
|August 14, 2020
PubMed
Summary

Immune checkpoint blockade (ICB) shows promise in hematological malignancies, but resistance limits long-term control. Exploring novel T-cell and innate immune checkpoints is crucial for improving ICB efficacy in these cancers.

Keywords:
Hematological malignancyImmune checkpoint moleculeImmunotherapyTumor microenvironment

More Related Videos

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.1K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

914

Related Experiment Videos

Last Updated: Dec 12, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.2K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.1K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

914

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Immune checkpoint blockade (ICB) therapies like anti-PD-1 and anti-CTLA-4 have revolutionized solid tumor treatment.
  • While immunotherapies improve hematological malignancy outcomes, ICB benefits are limited to specific immune-infiltrated tumors.
  • Primary and acquired resistance to ICB in hematological malignancies necessitates understanding disease-specific immune microenvironments.

Purpose of the Study:

  • To review recent advances in immune checkpoint blockade for hematological malignancies.
  • To explore emerging roles of T-cell and innate immune checkpoint molecules as therapeutic targets.
  • To discuss strategies for overcoming resistance and improving ICB efficacy.

Main Methods:

  • Literature review of recent advances in ICB for hematological malignancies.
  • Analysis of T-cell and innate immune checkpoint roles in hematological cancers.
  • Discussion of therapeutic strategies targeting immune checkpoints.

Main Results:

  • ICB efficacy in hematological malignancies is limited by resistance mechanisms.
  • Novel T-cell checkpoints (beyond PD-1, CTLA-4) and innate checkpoints (on NK cells, macrophages) show therapeutic potential.
  • Targeting innate checkpoints may enhance antibody-mediated cellular cytotoxicity and phagocytosis.

Conclusions:

  • Understanding disease-specific immune microenvironments is essential for improving ICB efficacy in hematological malignancies.
  • Targeting novel T-cell and innate immune checkpoints offers promising strategies to overcome resistance.
  • ICB, particularly combined with innate immune checkpoint blockade, holds significant potential for treating hematological cancers.